A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples